Browsing Tag
AVA6103
22 posts
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Will Avacta’s pre|CISION platform turn its £3.25m bond repayment into a precision oncology breakthrough?
Avacta Group plc raises £3.25M to repay its convertible bond and extend clinical runway for its pre|CISION cancer drugs—find out what’s next.